Literature DB >> 35749589

The Interaction of SWI/SNF with the Ribosome Regulates Translation and Confers Sensitivity to Translation Pathway Inhibitors in Cancers with Complex Perturbations.

Livia Ulicna1, Samuel C Kimmey1,2, Christopher M Weber1, Grace M Allard1, Aihui Wang1, Nam Q Bui2, Sean C Bendall1, Gerald R Crabtree1,3, Gregory R Bean1, Capucine Van Rechem1.   

Abstract

Subunits from the chromatin remodelers mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) are mutated, deleted, or amplified in more than 40% of cancers. Understanding their functions in normal cells and the consequences of cancerous alterations will provide insight into developing new targeted therapies. Here we examined whether mSWI/SNF mutations increase cellular sensitivity to specific drugs. Taking advantage of the DepMap studies, we demonstrate that cancer cells harboring mutations of specific mSWI/SNF subunits exhibit a genetic dependency on translation factors and are sensitive to translation pathway inhibitors. Furthermore, mSWI/SNF subunits were present in the cytoplasm and interacted with the translation initiation machinery, and short-term inhibition and depletion of specific subunits decreased global translation, implicating a direct role for these factors in translation. Depletion of specific mSWI/SNF subunits also increased sensitivity to mTOR-PI3K inhibitors. In patient-derived breast cancer samples, mSWI/SNF subunits expression in both the nucleus and the cytoplasm was substantially altered. In conclusion, an unexpected cytoplasmic role for mSWI/SNF complexes in translation suggests potential new therapeutic opportunities for patients afflicted by cancers demonstrating alterations in their subunits. SIGNIFICANCE: This work establishes direct functions for mSWI/SNF in translation and demonstrates that alterations in mSWI/SNF confer a therapeutic vulnerability to translation pathway inhibitors in cancer cells. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35749589      PMCID: PMC9379364          DOI: 10.1158/0008-5472.CAN-21-1360

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  29 in total

1.  Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

Authors:  Steve Bilodeau; Sophie Vallette-Kasic; Yves Gauthier; Dominique Figarella-Branger; Thierry Brue; France Berthelet; André Lacroix; Dalia Batista; Constantine Stratakis; Jeanette Hanson; Björn Meij; Jacques Drouin
Journal:  Genes Dev       Date:  2006-10-15       Impact factor: 11.361

2.  Direct interactions promote eviction of the Sir3 heterochromatin protein by the SWI/SNF chromatin remodeling enzyme.

Authors:  Benjamin J Manning; Craig L Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

3.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Authors:  Junya Fukuoka; Takeshi Fujii; Joanna H Shih; Tatiana Dracheva; Daoud Meerzaman; Audrey Player; Kyeong Hong; Sharon Settnek; Ajay Gupta; Kenneth Buetow; Stephen Hewitt; William D Travis; Jin Jen
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

4.  Cytoplasmic localization and nucleo-cytoplasmic shuttling of BAF53, a component of chromatin-modifying complexes.

Authors:  Jung Hwa Lee; Seok Hoon Chang; Jae Hwan Shim; Ji Yeon Lee; Minoru Yoshida; Hyockman Kwon
Journal:  Mol Cells       Date:  2003-08-31       Impact factor: 5.034

5.  Structure and biosynthesis of apolipoprotein B.

Authors:  S O Olofsson; K Boström; P Carlsson; J Borén; M Wettesten; G Bjursell; O Wiklund; G Bondjers
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

Review 6.  The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.

Authors:  Courtney Hodges; Jacob G Kirkland; Gerald R Crabtree
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

7.  mSWI/SNF promotes Polycomb repression both directly and through genome-wide redistribution.

Authors:  Christopher M Weber; Antonina Hafner; Jacob G Kirkland; Simon M G Braun; Benjamin Z Stanton; Alistair N Boettiger; Gerald R Crabtree
Journal:  Nat Struct Mol Biol       Date:  2021-06-11       Impact factor: 15.369

Review 8.  PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.

Authors:  Karolina N Dziadkowiec; Emilia Gąsiorowska; Ewa Nowak-Markwitz; Anna Jankowska
Journal:  Prz Menopauzalny       Date:  2017-02-08

9.  Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers.

Authors:  H Courtney Hodges; Benjamin Z Stanton; Katerina Cermakova; Chiung-Ying Chang; Erik L Miller; Jacob G Kirkland; Wai Lim Ku; Vaclav Veverka; Keji Zhao; Gerald R Crabtree
Journal:  Nat Struct Mol Biol       Date:  2017-12-11       Impact factor: 15.369

10.  The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A.

Authors:  Xiaoxian Sima; Jiangnan He; Jie Peng; Yanmei Xu; Feng Zhang; Libin Deng
Journal:  PLoS One       Date:  2019-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.